hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06374797 id: CMZ-207 briefTitle: A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk" acronym: KOURAGE overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-08 date: 2025-08 date: 2024-04-19 date: 2024-04-19 name: CalciMedica, Inc. class: INDUSTRY briefSummary: Approximately 150 patients with acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF) will be randomized at up to 40 sites. Patients will be randomly assigned to either Auxora or matching placebo. Study drug infusions will occur every 24 hours for five consecutive days for a total of five infusions. conditions: Acute Kidney Injury studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 150 type: ESTIMATED name: Auxora name: Placebo measure: Days alive, ventilator-free and kidney replacement therapy (KRT)-free from SFISD through Day 30 measure: Major adverse kidney event (MAKE) 90-1: ≥25% decline in estimated glomerular filtration rate (eGFR) from baseline, incident KRT, and all-cause mortality at 90 days measure: MAKE 90-2: ≥35% decline in eGFR from baseline, incident KRT, and all-cause mortality at 90 days measure: Proportion of patients alive at Day 30 measure: Proportion of patients alive at Day 90 measure: Days alive and ventilator-free from start of first infusion of study drug (SFISD) through Day 30 measure: Days alive and KRT-free from SFISD through Day 30 measure: Proportion of patients recovered from AHRF through Day 30 as categorized by an 8-point ordinal scale measure: Proportion of patients receiving KRT at Day 30 measure: Proportion of patients receiving KRT at Day 90 measure: Number of patients with treatment-related adverse events (TEAE) measure: Number of patients with grade 3 TEAEs measure: Days alive and not hospitalized through Day 30 measure: Proportion of patients re-hospitalized through Day 30 measure: Proportion of patients re-hospitalized through Day 90 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06374784 id: perio2023ARP briefTitle: Autogenous Demineralized Dentin Graft Combined With Injectable PRF + Metronidazole Versus Autogenous Demineralized Dentin Graft Combined With Injectable PRF Versus Autogenous Demineralized Dentin Graft Alone for Alveolar Ridge Preservation overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2024-10-20 date: 2024-11-20 date: 2024-04-19 date: 2024-04-23 name: Cairo University class: OTHER briefSummary: The aim of this trial is to compare the effect of autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole (sticky demineralized tooth releasing metronidazole) versus autogenous demineralized dentin graft combined with injectable PRF (sticky demineralized tooth) versus autogenous demineralized dentin graft (ADDG) alone on alveolar ridge preservation after extraction of non restorable, infected single-rooted teeth conditions: Alveolar Bone Loss studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole name: Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF name: Alveolar ridge preservation using autogenous demineralized dentin graft alone measure: Alveolar ridge apico-coronal height change in mm measure: Alveolar ridge bucco-lingual width change in mm measure: Histological assessment sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Faculty of Dentistry city: Cairo country: Egypt name: Cairo University role: CONTACT lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06374771 id: MD-15-2022 briefTitle: Analgesic Effect of Melatonin and Vitamin C Administration, Alone or In Combination in Major Abdominal Surgery. overallStatus: NOT_YET_RECRUITING date: 2024-04-27 date: 2024-06-27 date: 2024-07-10 date: 2024-04-19 date: 2024-04-19 name: Cairo University class: OTHER name: Theodor Bilharz Research Institute briefSummary: The goal of this clinical trial is to compare the analgesic effect of melatonin, and vitamin C and their combination in patients aged 18-60 years old who will undergo major abdominal surgery with mid-line incision within an expected time of surgery from 3 to 5 hours e.g. radical cystectomy, radical prostatectomy, colectomy, sigmoidectomy, splenectomy, and CBD exploration through mid-line incision.
Participants will be allocated into three equal groups: Melatonin (M group) and vitamin C (V group), and Melatonin and vitamin C (VM group). Two hours before surgery all patients will receive the study drugs orally and will be continued for 3 days postoperative at the same time of the first administration; 10mg of melatonin for M group (Melatonin 10 mg - Puritan's Pride premium company), 1gm of vitamin C for V group (Sanso C 1000 mg - AUG pharma company), and 10mg of melatonin and 1gm of vitamin C for VM group.
* The effect on the incidence of chronic post-surgical pain. conditions: Postoperative Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Melatonin 10 MG name: Vitamin C measure: Total morphine consumption measure: Numeric Rating Scale measure: Richmond Agitation Sedation Scale measure: Time to first analgesic request measure: chronic post-surgical pain measure: patient satisfaction using Likert three-point scale measure: systolic blood pressure measure: Heart rate measure: Intra-operative mean consumption of sevoflurane per hour. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Medicine - Cairo University city: Cairo state: Manial zip: 11553 country: Egypt name: Waleed Hamimy, MD role: CONTACT phone: 01150377770 phoneExt: +2 email: hamimy2002@gmail.com lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06374758 id: MU-2096449 briefTitle: Accelerated ART Initiation for PWHIV Who Are Out of Care acronym: ACCELERATE overallStatus: RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2025-11-01 date: 2024-04-19 date: 2024-04-19 name: University of Missouri-Columbia class: OTHER name: Gilead Sciences briefSummary: The main purpose of the study is to evaluate the effectiveness, of the ACCELERATE model of care to achieve HIV viral suppression at Week 24. The study will also assess the acceptability, appropriateness, feasibility, and sustainability of the ACCELERATE model of care. The ACCELERATE model combines a standardized method for outreach, the use of telehealth for rapid access to an HIV care provider, a simplified pre-approved HIV regimen, a free 30-day medication starter supply, and re-linkage to medical care. conditions: HIV Infections conditions: ART conditions: Noncompliance, Patient studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 120 type: ESTIMATED name: The Accelerate model of care name: bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg measure: The effectiveness of the ACCELERATE model of care to achieve HIV viral suppression at Week 24. measure: To study the change over time in the acceptability of the ACCELERATE model of care in patient and staff participants. measure: To study the change over time in appropriateness of the ACCELERATE model of care in patient and staff participants measure: To study the change over time in feasibility of the ACCELERATE model of care in patient and staff participants measure: To study the change over time in sustainability of the ACCELERATE model of care in patient and staff participants measure: Qualitative data measure: To evaluate the effectiveness of the intervention to achieve HIV viral suppression at week 48 using ACCELERATE model of care. measure: To assess change in patient experience (PROs) and satisfaction for participants using the ACCELERATE model of care measure: To assess change in health-related quality of life (HRQoL) measure: To measure the change in patients' satisfaction with the HIV treatment regimen B/F/TAF measure: To measure Retention in Care measure: To assess the adherence to the study treatment measure: To study the virologic response of using B/F/TAF as first line regimen in ACCELERATE model of care. measure: To study the immunologic response of using B/F/TAF as first line regimen in ACCELERATE model of care. measure: To assess staff impact of ACCELERATE model of care on staff satisfaction measure: To assess staff impact of ACCELERATE model of care on staff burnout sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Missouri-Columbia status: RECRUITING city: Columbia state: Missouri zip: 65212 country: United States name: Dima Dandachi, MD role: CONTACT phone: 573-884-8728 email: dandachid@health.missouri.edu lat: 38.95171 lon: -92.33407 hasResults: False
nctId: NCT06374745 id: 2020-01307; mu24Kappos briefTitle: An Integrated Algorithm for Surgical Intervention in Chronic Lymphedema After Breast Cancer Treatment: The Basel Lymphedema Protocol overallStatus: RECRUITING date: 2015-01-02 date: 2024-12-30 date: 2024-12-30 date: 2024-04-19 date: 2024-04-19 name: University Hospital, Basel, Switzerland class: OTHER name: Sana Kliniken Düsseldorf GmbH briefSummary: The primary objective of the investigators is to develop an integrated algorithm for surgical treatment of chronic lymphedema after breast cancer surgery. This will be achieved by retrospectively analysing a subgroup of patients who had breast cancer-related surgery prior to lymphedema. conditions: Lymphedema conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 500 type: ESTIMATED measure: To design an integrated algorithm for surgical treatment of chronic lymphedema after breast cancer surgery. measure: Date of follow-up procedure measure: Follow-up and type of lymphedema surgery measure: Circumferences of the affected and unaffected side measure: Postoperative complications measure: Surgery duration. measure: Type of lymphedema surgery measure: Date of lymphedema surgery measure: Use of compression stockings measure: Number of lymphedema drainages per week measure: Stage of lymphedema measure: Duration of lymphedema measure: Location of lymphedema measure: Subsequent cancer treatment measure: Date of cancer related surgery measure: Tumor staging measure: Tumor location measure: BMI measure: Comorbidities measure: Age measure: Gender measure: Analysis of cohort subgroups: all patients who had surgery related to any kind of cancer prior to their lymphedema measure: Analysis of cohort subgroups: all patients who had surgery related to a specific kind of cancer prior to their lymphedema, e.g. vulvar, cervical or uterine cancer measure: Analysis of cohort subgroups: all patients who had no history of cancer and thus no cancer-related surgery in their medical history measure: Analysis of cohort subgroups: all patients with chronic lymphedema regardless of whether or not they have an oncological history measure: Analysis of cohort subgroups: all patients who underwent DIEP flap or TRAM flap or LDM flap or implant based breast reconstruction or BCS measure: Analysis of cohort subgroups: exploratory sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Basel status: RECRUITING city: Basel zip: 4031 country: Switzerland name: Elisabeth A Kappos, PD Dr. med. role: CONTACT phone: 0041 61 265 25 25 email: elisabeth.kappos@usb.ch name: Adriano Fabi, BMed role: CONTACT phone: 0041 79 888 12 51 email: adriano.fabi@uzh.ch lat: 47.55839 lon: 7.57327 hasResults: False
nctId: NCT06374732 id: TY2024002 briefTitle: The Benefits of a High-intensity Interval Training Intervention Delivered in a School Setting Among Adolescents overallStatus: RECRUITING date: 2024-02-26 date: 2024-10-01 date: 2024-10-01 date: 2024-04-19 date: 2024-04-19 name: University of Exeter class: OTHER name: China Scholarship Council name: Ningbo University briefSummary: A 12-week school-based high-intensity interval training intervention, with 8 classes of year 7 students randomly allocated to either intervention or control group. The interval training sessions will last for 6 to 10 minutes and will be delivered 5 times per week. Outcome variables will be physical activity, body composition, cardiorespiratory fitness, muscular strength, bone health, executive function, mental wellbeing, and academic performance, which will be measured pre- and post-intervention and two months after the intervention has been completed. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 400 type: ESTIMATED name: High-intensity interval training name: Control group measure: Cardiorespiratory fitness measure: Muscular strength measure: Wellbeing measure: Enjoyment measure: Motivation measure: Affect measure: Academic performance measure: Height measure: Weight measure: BMI measure: Waist circumference measure: Body fat percentage measure: Physical activity measure: Bone health measure: Perceived physical ability measure: Flanker task measure: Visual 2-back task measure: Colour-shape switch task measure: Confounding variables measure: Interview sex: ALL minimumAge: 11 Years maximumAge: 13 Years stdAges: CHILD facility: University of Exeter status: RECRUITING city: Exeter state: Devon zip: EX1 2LU country: United Kingdom name: Yong Liu role: CONTACT phone: +447570013632 email: yl932@exeter.ac.uk role: CONTACT phoneExt: Liu email: yl932@exeter.ac.uk name: yong Liu role: PRINCIPAL_INVESTIGATOR lat: 50.7236 lon: -3.52751 hasResults: False
nctId: NCT06374719 id: WiTNNess briefTitle: WiTNNess - TNNT1 Myopathy Natural History Study acronym: WiTNNess overallStatus: RECRUITING date: 2018-09-23 date: 2027-01-01 date: 2027-06-01 date: 2024-04-19 date: 2024-04-19 name: Clinic for Special Children class: OTHER briefSummary: WiTNNess is designed to accurately document the natural course and variation of muscle disease caused by pathogenic changes of the TNNT1 gene. The primary aim of the study is to specify meaningful outcome measures for future clinical trials. WiTNNess is open to children and adults worldwide. Participants can choose to include their information once (cross-sectional cohort) or every few months (prospective cohort). conditions: TNNT1-associated Myopathy conditions: Infantile-onset Nemaline Rod Myopathy conditions: Myopathies, Nemaline conditions: Myopathy conditions: Myopathy, Rod conditions: Myopathy; Hereditary conditions: Amish Nemaline Myopathy conditions: Nemaline Myopathy 5 conditions: NEM5 conditions: Genetic Muscle Disease conditions: Recessive Hereditary Disorder (Autosomal) conditions: ANM studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED measure: Event-free survival measure: Motor Milestones measure: Thriving sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Clinic for Special Children status: RECRUITING city: Strasburg state: Pennsylvania zip: 17579 country: United States name: Joelle FS Williamson, MPH role: CONTACT phone: 717-687-9407 email: jwilliamson@clinicforspecialchildren.org lat: 39.98316 lon: -76.18412 hasResults: False
nctId: NCT06374706 id: 23-0129 briefTitle: Effects of End-Effector Type Rehabilitation Robots-Morning Walk on Symmetrical Walking Patterns in Individuals With Hemiparesis overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-04-01 date: 2025-08-30 date: 2024-04-19 date: 2024-04-19 name: The University of Texas Medical Branch, Galveston class: OTHER briefSummary: In this study, our objective is to explore and evaluate interventions to improve the process of recovery following a stroke. The main focus is on enhancing symmetrical walking patterns in adults who have experienced neurological deficits due to a stroke. The primary tool will be an end-effector type rehabilitation robot, the Morning Walk®. This robot has been specifically designed to assist in enhancing symmetrical walking patterns for individuals recovering from a stroke Morning Walk® has received approval from the FDA, meaning it meets stringent safety and efficacy standards. conditions: Stroke conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: Morning Walk training for stroke name: Morning Walk training for healthy measure: The Number of Participants with Kinematic representation of the temporal events during end-effector robot training measure: Muscle Activity in the lower extremities measure: Spatiotemporal Patterns of Walking, Speeds measure: Spatiotemporal Patterns of Walking, Parameters sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Texas Medical Branch city: Galveston state: Texas zip: 77555 country: United States name: Mansoo Ko, Ph.D. role: CONTACT phone: 409-772-9555 email: mako@utmb.edu name: Judith L Linton, MS role: CONTACT phone: 4092661767 email: jllinton@utmb.edu lat: 29.30135 lon: -94.7977 hasResults: False
nctId: NCT06374693 id: STH22772 briefTitle: Investigating the Tolerability and Feasibility of Transcutaneous Vagus Nerve Stimulation Following Aneurysmal Subarachnoid Haemorrhage acronym: tVNS in aSAH overallStatus: NOT_YET_RECRUITING date: 2024-04-14 date: 2025-08 date: 2025-08 date: 2024-04-19 date: 2024-04-19 name: Sheffield Teaching Hospitals NHS Foundation Trust class: OTHER briefSummary: After a subarachnoid haemorrhage, complications are common and increase the overall rate of disability and death from the condition. Despite some advances in preventing, detecting and treating these complications, the rates of complications and associated risks remain high. Further research into ways to reduce complications of subarachnoid haemorrhage.
They will continue to receive full medical treatment and observation alongside the study. They are free to withdraw from this study if they find it too demanding on top of their other activities. conditions: Subarachnoid Haemorrhage From Cerebral Aneurism Rupture studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Transcutaneous Vagus Nerve Stimulation name: Sham Transcutaneous Vagus Nerve Stimulation measure: Monitor tolerability for tVNS measure: Assess study feasibility measure: Monitor safety criteria for tVNS measure: Rates of delayed cerebral ischaemia (DCI) measure: Inpatient mortality measure: Length of inpatient stay measure: Rates of inpatient complications measure: Modified rankin score measure: Barthel Index measure: Inflammatory markers measure: Headache scores measure: Cerebral functional near-infrared spectroscopy measure: Heart rate variability measure: Pupillary light reactivity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Sheffield city: Sheffield state: South Yorkshire zip: S10 2HQ country: United Kingdom name: Dr Ali Ali role: CONTACT phone: +4401142159114 email: Ali.ali@sheffield.ac.uk name: Mr Matthew Myers role: SUB_INVESTIGATOR lat: 53.38297 lon: -1.4659 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-12-16 uploadDate: 2024-01-12T08:49 filename: Prot_000.pdf size: 2294124 hasResults: False
nctId: NCT06374680 id: C3 ectomy briefTitle: C3 Laminectomy With Cervical Laminoplasty overallStatus: WITHDRAWN date: 2017-03-20 date: 2021-12-31 date: 2021-12-31 date: 2024-04-19 date: 2024-04-22 name: Seoul National University Hospital class: OTHER briefSummary: 1. Background In cervical stenosis, cervical laminoplasty from the third to sixth cervical vertebrae is widely used. However, the muscles attached to the C2, which play an important role in the movement of our neck, are frequently damaged during the C3 laminoplasty. In contrast, cervical spine surgery through the removal of the C3 is thought to give less damage to the muscles attached to the C2.
3. Hypothesis There is no difference in the cervical length and overall cervical angle between 1 month, 3 months, 6 months, and 12 months postoperatively between C3 laminectomy with C4-6 laminoplasty and C3-6 laminoplasty. conditions: Neck Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 0 type: ACTUAL name: laminectomy at C3 level measure: neck pain sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital city: Seoul zip: 110-744 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06374667 id: KY2024-071-02 briefTitle: The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction acronym: SOLUTION-2 overallStatus: RECRUITING date: 2024-04-22 date: 2025-09-15 date: 2026-03-15 date: 2024-04-18 date: 2024-04-26 name: yilong Wang class: OTHER briefSummary: A pilot study confirmed the feasibility and safety of neuroprotectant Y-3 intracalvariosseous(ICO) injection in patients with malignant middle cerebral artery infarction (mMCAI), showing a trend in improving 90-day functional scores compared to conventional treatment. The aim of this trial is to further investigate the efficacy and safety of ICO injection of Y-3 compared to intravenous injection in patients with acute large hemispheric infarction(LHI) who has contraindications of reperfusion therapy or have got poor reperfusion therapy outcomes. conditions: Stroke, Acute Ischemic conditions: Blood-Brain Barrier studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Y-3 ICO injection name: Y-3 intravenous injection name: Conventional treatment measure: 90-day favorable clinical outcome measure: Change of infarct volume from baseline to 8-day measure: Neurofunctional deficit defined as the National Institutes of Health Stroke Scale (NIHSS) . measure: Patients with symptoms improvement from baseline to 14-day measure: Rate of decompressive hemicraniectomy measure: Depression scale scores at 90-day measure: Proportion of combined adverse events at 90-day sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The first affiliated hospital of Wannan Medical College status: NOT_YET_RECRUITING city: Wuhu state: Anhui country: China name: Shoucai Zhao, MD role: CONTACT name: Zhenbao Li, MD role: CONTACT lat: 31.33728 lon: 118.37351 facility: Beijing Tiantan Hospital status: RECRUITING city: Beijing state: Beijing zip: 100050 country: China name: Yilong Wang, PhD，MD role: CONTACT email: yilong538@gmail.com lat: 39.9075 lon: 116.39723 facility: Tangshan Municipal Worker's Hospital status: NOT_YET_RECRUITING city: Tangshan state: Heibei country: China name: Jun Hong, MD role: CONTACT lat: 39.63333 lon: 118.18333 facility: Shaanxi Provincial People's Hospital status: NOT_YET_RECRUITING city: Xi'an state: Shaanxi country: China name: Wei Hu, MD role: CONTACT lat: 34.25833 lon: 108.92861 hasResults: False